Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Upgraded by Zacks Investment Research

Regulus Therapeutics (NASDAQ:RGLS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday, Zacks.com reports. The brokerage currently has a $0.25 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target indicates a potential upside of 1.21% from the company’s current price.

According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “

RGLS stock opened at $0.25 on Thursday. The business’s fifty day simple moving average is $0.36 and its two-hundred day simple moving average is $0.57. Regulus Therapeutics has a twelve month low of $0.23 and a twelve month high of $2.32. The firm has a market cap of $21.50 million, a price-to-earnings ratio of -0.85 and a beta of 1.97.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Wednesday, November 10th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). During the same quarter in the previous year, the firm posted ($0.04) earnings per share. As a group, equities research analysts forecast that Regulus Therapeutics will post -0.33 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in RGLS. Morgan Stanley increased its stake in shares of Regulus Therapeutics by 2,799.7% during the first quarter. Morgan Stanley now owns 163,251 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 157,621 shares during the period. Commonwealth Equity Services LLC increased its stake in shares of Regulus Therapeutics by 300.0% during the second quarter. Commonwealth Equity Services LLC now owns 80,000 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 60,000 shares during the period. Lido Advisors LLC purchased a new position in shares of Regulus Therapeutics during the second quarter valued at $47,000. Geode Capital Management LLC increased its stake in shares of Regulus Therapeutics by 54.3% during the second quarter. Geode Capital Management LLC now owns 589,196 shares of the biopharmaceutical company’s stock valued at $479,000 after buying an additional 207,304 shares during the period. Finally, State Street Corp purchased a new position in shares of Regulus Therapeutics during the second quarter valued at $144,000. Hedge funds and other institutional investors own 43.14% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Featured Article: What is a stock buyback?

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.